In vitro and in vivo Evaluation of Antitumor Drug-Loaded Aptamer Targeted Single-Walled Carbon Nanotubes System

Zhang, Huijuan; Hou, Lin; Jiao, Xiaojing; Ji, Yandan; Zhu, Xiali; Li, Hongji; Chen, Xiaozhe; Ren, Junxiao; Xia, Yadan; Zhang, Zhenzhong

doi:10.2174/1389201015666140408123710

Cited by 37 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, AS1411 can induce an S-phrase cell cycle arrest in gastric cancer cells [51] and PC3 cancer cells [52]. While in our study, obvious G2/M arrest was induced by AS1411 in U87 and U251 cells.…”

Section: Discussionmentioning

confidence: 47%

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin

et al. 2016

View full text Add to dashboard Cite

AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the treatment of several cancers. However, the mechanisms by which AS1411 targets and kills glioma cells and tissues remain unclear. Here we report that AS1411 induces cell apoptosis and cycle arrest, and inhibits cell viability by up-regulation of p53 and down-regulation of Bcl-2 and Akt1 in human glioma cells. NCL was overexpressed in both nucleus and cytoplasm in human glioma U87, U251 and SHG44 cells compared to normal human astrocytes (NHA). AS1411 bound NCL and inhibited the proliferation of glioma cells but not NHA, which was accompanied with up-regulation of p53 and down-regulation of Bcl-2 and Akt1. Moreover, AS1411 treatment resulted in the G2/M cell cycle arrest in glioma cells, which was however abolished by overexpression of NCL. Further, AS1411 induced cell apoptosis, which was prevented by silencing of p53 and overexpression of Bcl-2. In addition, AS1411 inhibited the migration and invasion of glioma cells in an Akt1-dependent manner. Importantly, AS1411 inhibited the growth of glioma xenograft and prolonged the survival time of glioma tumor-bearing mice. These results revealed a promising treatment of glioma by oligodeoxynucleotide aptamer.

show abstract

Section: Discussionmentioning

confidence: 47%

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recently, AS1411 has been largely employed as a selective nucleolin-targeting agent, successfully combined with chemotherapeutic agents (such as paclitaxel [228][229][230][231], docetaxel [232][233][234], doxorubicin [235][236][237][238][239][240][241][242][243][244], and epirubicin) [245] onto suitable nanosystems in the context of specific recognition of cancer cells and tumour-selective delivery of therapeutic or imaging agents for cancer treatment [227].…”

Section: Improved Ru(iii)-containing Nanosystems: Introduction Of Tarmentioning

confidence: 99%

Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

et al. 2019

View full text Add to dashboard Cite

The great advances in the studies on metal complexes for the treatment of different cancer forms, starting from the pioneering works on platinum derivatives, have fostered an increasingly growing interest in their properties and biomedical applications. Among the various metal-containing drugs investigated thus far, ruthenium(III) complexes have emerged for their selective cytotoxic activity in vitro and promising anticancer properties in vivo, also leading to a few candidates in advanced clinical trials. Aiming at addressing the solubility, stability and cellular uptake issues of low molecular weight Ru(III)-based compounds, some research groups have proposed the development of suitable drug delivery systems (e.g., taking advantage of nanoparticles, liposomes, etc.) able to enhance their activity compared to the naked drugs. This review highlights the unique role of Ru(III) complexes in the current panorama of anticancer agents, with particular emphasis on Ru-containing nanoformulations based on the incorporation of the Ru(III) complexes into suitable nanocarriers in order to enhance their bioavailability and pharmacokinetic properties. Preclinical evaluation of these nanoaggregates is discussed with a special focus on the investigation of their mechanism of action at a molecular level, highlighting their pharmacological potential in tumour disease models and value for biomedical applications.

show abstract

“…Como en el caso de las NP, podríamos aprovechar que se acumulan en el estroma de los tumores debido a su mayor permeabilidad a través de vasos capilares formados para nutrir al tumor, y tras aplicar un láser u otra fuente de iluminación se podría destruir un tumor por fotoablación [114][115][116] .…”

Section: Fotoablación Con Nanopartículas Metálicasunclassified

Perspectivas de futuro en láseres, nuevas tecnologías y nanotecnología en dermatología

Boixeda

Feltes

Santiago

et al. 2015

Actas Dermo-Sifiliográficas

View full text Add to dashboard Cite

In vitro and in vivo Evaluation of Antitumor Drug-Loaded Aptamer Targeted Single-Walled Carbon Nanotubes System

Cited by 37 publications

References 0 publications

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin

Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

Perspectivas de futuro en láseres, nuevas tecnologías y nanotecnología en dermatología

Contact Info

Product

Resources

About